Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term growth-factor. Found 33 abstracts

no pagination
Cukierman E, Bassi DE. The mesenchymal tumor microenvironment A drug-resistant niche. Cell Adhesion & Migration. 2012 May;6(3):285-96.   PMCID: PMC3427243
Dawood S, Shaikh AJ, Buchholz TA, Cortes J, Cristofanilli M, Gupta S, Gonzalez-Angulo AM. The use of bevacizumab among women with metastatic breast cancer: A survey on clinical practice and the ongoing controversy. Cancer. 2012 Jun;118(11):2780-6.   PMCID: *
Hough C, Radu M, Dore JJ. TGF-Beta Induced Erk Phosphorylation of Smad Linker Region Regulates Smad Signaling. PLoS One. 2012 Aug;7(8):e42513.   PMCID: PMC3412844
Argiris A, Ghebremichael M, Burtness B, Axelrod RS, Deconti RC, Forastiere AA. A Phase 2 Trial of Bortezomib Followed by the Addition of Doxorubicin at Progression in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck A Trial of the Eastern Cooperative Oncology Group (E1303). Cancer. 2011 Aug;117(15):3374-82.   PMCID: PMC3135694
Astsaturov IA, Meropol NJ, Alpaugh RK, Burtness BA, Cheng JD, McLaughlin S, Rogatko A, Xu ZH, Watson JC, Weiner LM, Cohen SJ. Phase II and Coagulation Cascade Biomarker Study of Bevacizumab With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma. American Journal of Clinical Oncology-Cancer Clinical Trials. 2011 Feb;34(1):70-5.   PMCID: PMC3030655
Dawood S, Cristofanilli M. Inflammatory Breast Cancer: What Progress Have We Made?. Oncology-New York. 2011 Mar;25(3):264-73.   PMCID: not NIH funded
Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S, Robertson FM, Woodward WA, Yang WT, Ueno NT, Cristofanilli M. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Annals of Oncology. 2011 Mar;22(3):515-23.   PMCID: PMC3105293
del Monte G, Casanova JC, Guadix JA, MacGrogan D, Burch JB, Perez-Pomares JM, de la Pompa JL. Differential Notch Signaling in the Epicardium Is Required for Cardiac Inflow Development and Coronary Vessel Morphogenesis. Circulation research. 2011 Apr;108(7):824-U137.   PMCID: *
Heath EI, Blumenschein GR, Cohen RB, LoRusso PM, LoConte NK, Kim ST, Ruiz-Garcia A, Chao RC, Wilding G. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. Cancer Chemotherapy and Pharmacology. 2011 Sep;68(3):703-12.   PMCID: not NIH funded
Banumathy G, Cairns P. Signaling pathways in renal cell carcinoma. Cancer Biology & Therapy. 2010 Oct;10(7):658-64.   PMCID: PMC3093809
Tan YF, Cheung M, Pei JM, Menges CW, Godwin AK, Testa JR. Upregulation of DLX5 Promotes Ovarian Cancer Cell Proliferation by Enhancing IRS-2-AKT Signaling. Cancer Research. 2010 Nov;70(22):9197-206.   PMCID: PMCID: PMC3018149 [Available on 2011/11/1]
Natarajan M, Stewart JE, Golemis EA, Pugacheva EN, Alexandropoulos K, Cox BD, Wang W, Grammer JR, Gladson CL. HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells. ONCOGENE. 2006 Mar;25(12):1721-32.
Pan ZZ, Bruening W, Godwin AK. Involvement of RHO GTPases and ERK in synuclein-gamma enhanced cancer cell motility. INTERNATIONAL JOURNAL OF ONCOLOGY. 2006 Nov;29(5):1201-5.
Cacciotti P, Barbone D, Porta C, Altomare DA, Testa JR, Mutti L, Gaudino G. SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure. Cancer Research. 2005 Jun 15;65(12):5256-62.
Guerrico AM, Jaffer ZM, Page RE, Braunewell KH, Chernoff J, Klein-Szanto AJ. Visinin-like protein-1 is a potent inhibitor of cell adhesion and migration in squamous carcinoma cells. Oncogene. 2005 Mar 31;24(14):2307-16.
von Mehren M, Watson JC. Gastrointestinal stromal tumors. Hematology-Oncology Clinics of North America. 2005 Jun;19(3):547-+.
Al Moustafa AE, Foulkes WD, Wong A, Jallal H, Batist G, Yu QY, Herlyn M, Sicinski P, Alaoui-Jamali MA. Cyclin D1 is essential for neoplastic transformation induced by both E6/E7 and E6/E7/ErbB-2 cooperation in normal cells. Oncogene. 2004 Jul;23(30):5252-6.
Haglund K, Ivankovic-Dikic I, Shimokawa N, Kruh GD, Dikic I. Recruitment of Pyk2 and Cbl to lipid rafts mediates signals important for actin reorganization in growing neurites. Journal of cell science. 2004 May;117(12):2557-68.
Hogarth DK, Sandbo N, Taurin S, Kolenko V, Miano JM, Dulin NO. Dual role of PKA in phenotypic modulation of vascular smooth muscle cells by extracellular ATP. American Journal of Physiology-Cell Physiology. 2004 Aug;287(2):C449-C456.
Sauter ER, Yeo UC, von Stemm A, Zhu WZ, Litwin S, Tichansky DS, Pistritto G, Nesbit M, Pinkel D, Herlyn M, Bastian BC. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Research. 2002 Jun;62(11):3200-6.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term growth-factor

growth-factor expression tyrosine kinase inhibitor activation in-vivo plus phase-ii overexpression bevacizumab carcinoma apoptosis phosphatidylinositol 3-kinase endothelial gene-expression therapy neoadjuvant chemotherapy family bcl-2 of-function mutations heart stress fibers 1980 nnock if-v46-p452 synuclein-gamma RCC cells epdcs v-src deregulation vasculogenesis breast cancer bevacizumab-survey-FDA-controversy cells calponin gene migraition sv40 alpha(v) integrins kidney cancer multiple-myeloma cells chemotherapeutic-agents adjuvant chemotherapy squamous-cell carcinoma transcription malignant mesothelioma guidelines mutations tumor-stromal interactions tumor microenvironment-stromal-induced drug resistance-extracellular matrix-tumor-associated or carcinoma-associated fibroblasts-matrix-induced drug resistance-mesenchymal stroma myc protein stability antitumor-activity protooncogene pancreatic-cancer homeobox gene-expression squamous cell carcinoma (SCC) breast-cancer stage-iii ii trial adhesion-mediated drug salivary-gland carcinomas 2008 iorean eg-v26-p2008 stem-cell transplantation tumorigenesis plus gemcitabine cancer kappa-b-alpha gene stimulation protein-kinase-a complex-formation colorectal-cancer hypoxia-inducible factor-1 cervical-cancer focal tyrosine kinase kinase bone-marrow microenvironment c-myc visinin-like protein-1 (VILIP-1) lung-cancer pancreatic adenocarcinoma experience metabolism plasma-levels rhoc-gtpase ovarian cancer deprivation-induced apoptosis docking protein signaling pathways retinoic acid chromosome 11q13 amplification c-cbl GTPase Sunitinib kinase-a Oncology Antiangiogenesis down-regulation cell motility breast-cancer cells adhesion gene amplification tyrosine phosphorylation pleural mesothelioma Chemotherapy head and neck cancer ERK phosphoinositide 3-kinase coagulation uterine cervix NSCLC human-papillomavirus infection positron-emission-tomography coronary vessel development epicardium-Notch-Wilms tumor-1 system kinases transformation c-kit extracellular-matrix proteasome inhibitor ps-341 soft-tissue sarcomas cell lung-cancer inflammatory breast cancer breast cancer adhesion kinase serum response factor epigenetics alpha(v)beta(3) integrin chemotherapy HEF1 FAK-CAS-Crk-associated substrate-glioblastoma-migration in-vitro angiogenesis genetics RHO ras Cbl Pyk2-ArgBP2-PC12 cells-neurite outgrowth-lipid rafts src family kinases minimal residual disease ii receptor factor-i receptor p53 doxorubicin interstitial-cells induction chemotherapy large t-antigen chronic myeloid-leukemia survival astrocytic tumors adenoid cystic carcinoma proepicardium tumor invasion cancer-therapy integrin alpha-v-beta-3 prognostic-factors laparoscopic wedge resection Solid tumor
Last updated on Friday, January 03, 2020